Clinical Trial

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hippocampus is a brain structure that is important for memory. Memantine is a drug that is given to help relieve symptoms that can be caused by WBRT, including problems with memory and other mental symptoms. Health Canada, the regulatory body that oversees the use of drugs in Canada, has not approved the sale or use of memantine in combination with WBRT to treat this kind of cancer, although they have allowed its use in this study.
Protocol Amendment History 57 amendments
This ClinicalTrials.gov record has been amended 57 times since 2018-06-06; most recent amendment 2026-06-08.
Status change: Not Yet Recruiting → Recruiting 2018-08-20
Trial Details
NCT Number NCT03550391
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Alliance for Clinical Trials in Oncology, NRG Oncology
Conditions Brain Metastases
Enrollment 206 participants
Start Date 2018-11-22
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-09